Go Pro
→ AI Is Coming for Your Money (From Priority Gold) (Ad)tc pixel Free IVF Stock Alerts

INVO Fertility (IVF) Competitors

INVO Fertility logo
$1.06 0.00 (-0.09%)
As of 11:59 AM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

IVF vs. BMGL, MGRX, GXAI, AIDX, and NIVF

Should you buy INVO Fertility stock or one of its competitors? MarketBeat compares INVO Fertility with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with INVO Fertility include Basel Medical Group (BMGL), Mangoceuticals (MGRX), Gaxos.ai (GXAI), 20/20 Biolabs (AIDX), and NewGenIvf Group (NIVF). These companies are all part of the "healthcare services" industry.

How does INVO Fertility compare to Basel Medical Group?

INVO Fertility (NASDAQ:IVF) and Basel Medical Group (NASDAQ:BMGL) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, profitability, dividends, media sentiment and institutional ownership.

INVO Fertility currently has a consensus target price of $20.00, indicating a potential upside of 1,795.73%. Given INVO Fertility's stronger consensus rating and higher possible upside, equities research analysts clearly believe INVO Fertility is more favorable than Basel Medical Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
INVO Fertility
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
2.50
Basel Medical Group
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Basel Medical Group has a net margin of 0.00% compared to INVO Fertility's net margin of -183.75%. Basel Medical Group's return on equity of 0.00% beat INVO Fertility's return on equity.

Company Net Margins Return on Equity Return on Assets
INVO Fertility-183.75% -420.62% -45.21%
Basel Medical Group N/A N/A N/A

In the previous week, Basel Medical Group had 1 more articles in the media than INVO Fertility. MarketBeat recorded 1 mentions for Basel Medical Group and 0 mentions for INVO Fertility. INVO Fertility's average media sentiment score of 0.00 equaled Basel Medical Group'saverage media sentiment score.

Company Overall Sentiment
INVO Fertility Neutral
Basel Medical Group Neutral

Basel Medical Group has higher revenue and earnings than INVO Fertility.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
INVO Fertility$6.84M0.35-$25.13M-$352.18N/A
Basel Medical Group$8.90M0.91-$9.50MN/AN/A

12.0% of INVO Fertility shares are owned by institutional investors. 0.4% of INVO Fertility shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

INVO Fertility has a beta of 2.32, indicating that its share price is 132% more volatile than the broader market. Comparatively, Basel Medical Group has a beta of 0.24, indicating that its share price is 76% less volatile than the broader market.

Summary

Basel Medical Group beats INVO Fertility on 7 of the 13 factors compared between the two stocks.

How does INVO Fertility compare to Mangoceuticals?

Mangoceuticals (NASDAQ:MGRX) and INVO Fertility (NASDAQ:IVF) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, risk, media sentiment, profitability and valuation.

INVO Fertility has a net margin of -183.75% compared to Mangoceuticals' net margin of -4,639.13%. Mangoceuticals' return on equity of -112.00% beat INVO Fertility's return on equity.

Company Net Margins Return on Equity Return on Assets
Mangoceuticals-4,639.13% -112.00% -104.96%
INVO Fertility -183.75%-420.62%-45.21%

In the previous week, Mangoceuticals had 8 more articles in the media than INVO Fertility. MarketBeat recorded 8 mentions for Mangoceuticals and 0 mentions for INVO Fertility. Mangoceuticals' average media sentiment score of 0.39 beat INVO Fertility's score of 0.00 indicating that Mangoceuticals is being referred to more favorably in the media.

Company Overall Sentiment
Mangoceuticals Neutral
INVO Fertility Neutral

Mangoceuticals has higher earnings, but lower revenue than INVO Fertility. Mangoceuticals is trading at a lower price-to-earnings ratio than INVO Fertility, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mangoceuticals$460K19.86-$20.64M-$1.49N/A
INVO Fertility$6.84M0.35-$25.13M-$352.18N/A

INVO Fertility has a consensus price target of $20.00, indicating a potential upside of 1,795.73%. Given INVO Fertility's stronger consensus rating and higher probable upside, analysts clearly believe INVO Fertility is more favorable than Mangoceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mangoceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
INVO Fertility
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
2.50

Mangoceuticals has a beta of 2.09, meaning that its stock price is 109% more volatile than the broader market. Comparatively, INVO Fertility has a beta of 2.32, meaning that its stock price is 132% more volatile than the broader market.

56.7% of Mangoceuticals shares are owned by institutional investors. Comparatively, 12.0% of INVO Fertility shares are owned by institutional investors. 16.0% of Mangoceuticals shares are owned by company insiders. Comparatively, 0.4% of INVO Fertility shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Mangoceuticals and INVO Fertility tied by winning 8 of the 16 factors compared between the two stocks.

How does INVO Fertility compare to Gaxos.ai?

INVO Fertility (NASDAQ:IVF) and Gaxos.ai (NASDAQ:GXAI) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, earnings, institutional ownership, profitability, valuation and risk.

INVO Fertility has a beta of 2.32, indicating that its stock price is 132% more volatile than the broader market. Comparatively, Gaxos.ai has a beta of 0.94, indicating that its stock price is 6% less volatile than the broader market.

Gaxos.ai has a net margin of -131.28% compared to INVO Fertility's net margin of -183.75%. Gaxos.ai's return on equity of -34.42% beat INVO Fertility's return on equity.

Company Net Margins Return on Equity Return on Assets
INVO Fertility-183.75% -420.62% -45.21%
Gaxos.ai -131.28%-34.42%-33.12%

12.0% of INVO Fertility shares are held by institutional investors. Comparatively, 42.6% of Gaxos.ai shares are held by institutional investors. 0.4% of INVO Fertility shares are held by insiders. Comparatively, 3.2% of Gaxos.ai shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Gaxos.ai has lower revenue, but higher earnings than INVO Fertility. Gaxos.ai is trading at a lower price-to-earnings ratio than INVO Fertility, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
INVO Fertility$6.84M0.35-$25.13M-$352.18N/A
Gaxos.ai$1.93M3.15-$3.90M-$0.63N/A

In the previous week, Gaxos.ai had 2 more articles in the media than INVO Fertility. MarketBeat recorded 2 mentions for Gaxos.ai and 0 mentions for INVO Fertility. Gaxos.ai's average media sentiment score of 1.23 beat INVO Fertility's score of 0.00 indicating that Gaxos.ai is being referred to more favorably in the news media.

Company Overall Sentiment
INVO Fertility Neutral
Gaxos.ai Positive

INVO Fertility currently has a consensus target price of $20.00, suggesting a potential upside of 1,795.73%. Given INVO Fertility's stronger consensus rating and higher probable upside, equities research analysts clearly believe INVO Fertility is more favorable than Gaxos.ai.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
INVO Fertility
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
2.50
Gaxos.ai
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Gaxos.ai beats INVO Fertility on 10 of the 16 factors compared between the two stocks.

How does INVO Fertility compare to 20/20 Biolabs?

20/20 Biolabs (NASDAQ:AIDX) and INVO Fertility (NASDAQ:IVF) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, media sentiment, risk, valuation and earnings.

20/20 Biolabs currently has a consensus price target of $5.00, suggesting a potential upside of 1,026.13%. INVO Fertility has a consensus price target of $20.00, suggesting a potential upside of 1,795.73%. Given INVO Fertility's stronger consensus rating and higher probable upside, analysts clearly believe INVO Fertility is more favorable than 20/20 Biolabs.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
20/20 Biolabs
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
INVO Fertility
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
2.50

In the previous week, 20/20 Biolabs had 1 more articles in the media than INVO Fertility. MarketBeat recorded 1 mentions for 20/20 Biolabs and 0 mentions for INVO Fertility. 20/20 Biolabs' average media sentiment score of 0.00 equaled INVO Fertility'saverage media sentiment score.

Company Overall Sentiment
20/20 Biolabs Neutral
INVO Fertility Neutral

20/20 Biolabs has a net margin of 0.00% compared to INVO Fertility's net margin of -183.75%. 20/20 Biolabs' return on equity of 0.00% beat INVO Fertility's return on equity.

Company Net Margins Return on Equity Return on Assets
20/20 BiolabsN/A N/A N/A
INVO Fertility -183.75%-420.62%-45.21%

20/20 Biolabs has higher earnings, but lower revenue than INVO Fertility. 20/20 Biolabs is trading at a lower price-to-earnings ratio than INVO Fertility, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
20/20 Biolabs$2.05M2.65-$3.74M-$0.28N/A
INVO Fertility$6.84M0.35-$25.13M-$352.18N/A

12.0% of INVO Fertility shares are owned by institutional investors. 29.8% of 20/20 Biolabs shares are owned by company insiders. Comparatively, 0.4% of INVO Fertility shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

20/20 Biolabs beats INVO Fertility on 9 of the 15 factors compared between the two stocks.

How does INVO Fertility compare to NewGenIvf Group?

NewGenIvf Group (NASDAQ:NIVF) and INVO Fertility (NASDAQ:IVF) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

NewGenIvf Group has higher earnings, but lower revenue than INVO Fertility.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NewGenIvf Group$4.73M0.82$9.88MN/AN/A
INVO Fertility$6.84M0.35-$25.13M-$352.18N/A

NewGenIvf Group has a beta of 0.01, indicating that its stock price is 99% less volatile than the broader market. Comparatively, INVO Fertility has a beta of 2.32, indicating that its stock price is 132% more volatile than the broader market.

NewGenIvf Group has a net margin of 0.00% compared to INVO Fertility's net margin of -183.75%. NewGenIvf Group's return on equity of 0.00% beat INVO Fertility's return on equity.

Company Net Margins Return on Equity Return on Assets
NewGenIvf GroupN/A N/A N/A
INVO Fertility -183.75%-420.62%-45.21%

INVO Fertility has a consensus target price of $20.00, indicating a potential upside of 1,795.73%. Given INVO Fertility's stronger consensus rating and higher possible upside, analysts plainly believe INVO Fertility is more favorable than NewGenIvf Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NewGenIvf Group
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
INVO Fertility
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
2.50

In the previous week, NewGenIvf Group's average media sentiment score of 0.00 equaled INVO Fertility'saverage media sentiment score.

Company Overall Sentiment
NewGenIvf Group Neutral
INVO Fertility Neutral

66.2% of NewGenIvf Group shares are held by institutional investors. Comparatively, 12.0% of INVO Fertility shares are held by institutional investors. 31.8% of NewGenIvf Group shares are held by insiders. Comparatively, 0.4% of INVO Fertility shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

NewGenIvf Group beats INVO Fertility on 7 of the 12 factors compared between the two stocks.

Get INVO Fertility News Delivered to You Automatically

Sign up to receive the latest news and ratings for IVF and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IVF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IVF vs. The Competition

Export
MetricINVO FertilityHealthcare Providers & Services IndustryHealthcare SectorNASDAQ Exchange
Market Cap$2.43M$10.01B$7.03B$12.96B
Dividend YieldN/A2.55%2.58%10.20%
P/E Ratio0.0025.52269.9124.87
Price / Sales0.354.85654.69108.21
Price / CashN/A25.5828.8937.44
Price / Book0.305.3311.406.45
Net Income-$25.13M$309.96M$3.45B$347.50M
7 Day Performance8.21%0.76%3.66%3.77%
1 Month Performance-6.64%0.23%-0.49%-0.40%
1 Year Performance-98.53%23.46%77.51%23.55%

INVO Fertility Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IVF
INVO Fertility
2.43 of 5 stars		$1.06
-0.1%		$20.00
+1,788.6%		-98.5%$2.42M$6.84MN/A10
BMGL
Basel Medical Group
0.1469 of 5 stars		$5.89
+3.9%		N/A-77.5%$9.19M$8.90MN/A36
MGRX
Mangoceuticals
1.2376 of 5 stars		$0.45
-1.4%		N/A-73.5%$7.75M$460KN/A3
GXAI
Gaxos.ai
1.3234 of 5 stars		$0.89
-1.6%		N/A-19.8%$6.34M$1.93MN/A3
AIDX
20/20 Biolabs
1.5605 of 5 stars		$0.44
-3.2%		$5.00
+1,033.0%		N/A$5.41M$1.84MN/A14

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:IVF) was last updated on 8/10/2026 by MarketBeat.com Staff.
From Our Partners
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
Barricks gold output fell from 2 million ounces to 719000
Barrick's gold production has plunged from 2 million ounces to just 719,000, leaving the world's second-larges...
Golden Portfolio | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Beginner’s Guide to Gold
The Ultimate Beginner's Guide to Gold IRAs Protect Your Retirement Savings Before It's Too Late With This I...
Goldco Direct, LLC | Sponsoredtc pixel
China is not hedging. It's escaping.
China's US Treasury holdings have fallen from a peak of $1.32 trillion to roughly $659 billion, an 18-year low...
Behind the Markets | Sponsoredtc pixel
The ultimate IPO unicorn
Anthropic is now worth more than a trillion dollars, making it the first private company to reach that milesto...
Weiss Ratings | Sponsoredtc pixel
Free Stock Pick: The Company First in Line for America’s New Super Fuel
The U.S. Army and Department of Energy are launching Project Janus - a high-priority initiative ordered by Pre...
Banyan Hill Publishing | Sponsoredtc pixel